Bristol Myers Squibb is paying Prime Medicine $110 million upfront to develop reagents for ex vivo T-cell therapies. Prime, ...

Meanwhile, the acquisition of AntlerA, which Roche called a leader in Wnt signaling, gives the pharma ownership of a library ...

Tampa’s Moffitt Cancer Center is forging an international partnership with Japan’s largest CRO, CMIC, to improve the ability ...

Merck & Co. has picked up options on two Evaxion vaccine candidates, paying $3.2 million and dangling more than $1 billion in ...

Mendaera has raised $73 million in venture capital funding to continue the development of its handheld robotics platform for ...

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...

The NIH has found evidence of research misconduct against Eliezer Masliah, M.D., the longtime head of the National Institute ...

While Windtree Therapeutics has struggled to grow the financial roots needed to survive, a phase 2 win for the biotech’s lead ...

AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That ...

BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...

Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...

Amid the genetic medicines arms race, Flagship Pioneering is unveiling a new company to help biotechs fine-tune the precision ...